Compare MNSB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNSB | ADCT |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.1M | 136.1M |
| IPO Year | 2017 | 2019 |
| Metric | MNSB | ADCT |
|---|---|---|
| Price | $25.02 | $1.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 20.4K | ★ 1.5M |
| Earning Date | 04-20-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ 210.00 | 30.86 |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $135,615,000.00 | $81,357,000.00 |
| Revenue This Year | $1.50 | N/A |
| Revenue Next Year | $3.77 | $66.49 |
| P/E Ratio | $23.50 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $17.86 | $0.78 |
| 52 Week High | $25.87 | $4.98 |
| Indicator | MNSB | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).